These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 19073149)

  • 1. Regression of prostate cancer xenografts by RLIP76 depletion.
    Singhal SS; Roth C; Leake K; Singhal J; Yadav S; Awasthi S
    Biochem Pharmacol; 2009 Mar; 77(6):1074-83. PubMed ID: 19073149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RLIP76: a target for kidney cancer therapy.
    Singhal SS; Singhal J; Yadav S; Sahu M; Awasthi YC; Awasthi S
    Cancer Res; 2009 May; 69(10):4244-51. PubMed ID: 19417134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RLIP depletion induces apoptosis associated with inhibition of JAK2/STAT3 signaling in melanoma cells.
    Singhal SS; Mohanty A; Kulkarni P; Horne D; Awasthi S; Salgia R
    Carcinogenesis; 2021 May; 42(5):742-752. PubMed ID: 33623991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regression of lung and colon cancer xenografts by depleting or inhibiting RLIP76 (Ral-binding protein 1).
    Singhal SS; Singhal J; Yadav S; Dwivedi S; Boor PJ; Awasthi YC; Awasthi S
    Cancer Res; 2007 May; 67(9):4382-9. PubMed ID: 17483352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regression of melanoma in a murine model by RLIP76 depletion.
    Singhal SS; Awasthi YC; Awasthi S
    Cancer Res; 2006 Feb; 66(4):2354-60. PubMed ID: 16489041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rlip76 transports sunitinib and sorafenib and mediates drug resistance in kidney cancer.
    Singhal SS; Sehrawat A; Sahu M; Singhal P; Vatsyayan R; Rao Lelsani PC; Yadav S; Awasthi S
    Int J Cancer; 2010 Mar; 126(6):1327-38. PubMed ID: 19626587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The non-ABC drug transporter RLIP76 (RALBP-1) plays a major role in the mechanisms of drug resistance.
    Awasthi YC; Sharma R; Yadav S; Dwivedi S; Sharma A; Awasthi S
    Curr Drug Metab; 2007 May; 8(4):315-23. PubMed ID: 17504221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting p53-null neuroblastomas through RLIP76.
    Singhal J; Yadav S; Nagaprashantha LD; Vatsyayan R; Singhal SS; Awasthi S
    Cancer Prev Res (Phila); 2011 Jun; 4(6):879-89. PubMed ID: 21411502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2'-Hydroxyflavanone inhibits in vitro and in vivo growth of breast cancer cells by targeting RLIP76.
    Singhal J; Chikara S; Horne D; Salgia R; Awasthi S; Singhal SS
    Mol Carcinog; 2018 Dec; 57(12):1751-1762. PubMed ID: 30136444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. POB1 over-expression inhibits RLIP76-mediated transport of glutathione-conjugates, drugs and promotes apoptosis.
    Yadav S; Zajac E; Singhal SS; Singhal J; Drake K; Awasthi YC; Awasthi S
    Biochem Biophys Res Commun; 2005 Mar; 328(4):1003-9. PubMed ID: 15707977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RLIP76: A novel glutathione-conjugate and multi-drug transporter.
    Singhal SS; Yadav S; Roth C; Singhal J
    Biochem Pharmacol; 2009 Mar; 77(5):761-9. PubMed ID: 18983828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RLIP76 transports vinorelbine and mediates drug resistance in non-small cell lung cancer.
    Stuckler D; Singhal J; Singhal SS; Yadav S; Awasthi YC; Awasthi S
    Cancer Res; 2005 Feb; 65(3):991-8. PubMed ID: 15705900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RLIP76 Inhibition: A Promising Developmental Therapy for Neuroblastoma.
    Singhal SS; Nagaprashantha L; Singhal P; Singhal S; Singhal J; Awasthi S; Horne D
    Pharm Res; 2017 Aug; 34(8):1673-1682. PubMed ID: 28386633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Depletion of RLIP76 sensitizes lung cancer cells to doxorubicin.
    Singhal SS; Yadav S; Singhal J; Zajac E; Awasthi YC; Awasthi S
    Biochem Pharmacol; 2005 Aug; 70(3):481-8. PubMed ID: 15950949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RLIP76 is overexpressed in human glioblastomas and is required for proliferation, tumorigenesis and suppression of apoptosis.
    Wang Q; Wang JY; Zhang XP; Lv ZW; Fu D; Lu YC; Hu GH; Luo C; Chen JX
    Carcinogenesis; 2013 Apr; 34(4):916-26. PubMed ID: 23276796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RLIP76 (RALBP1)-mediated transport of leukotriene C4 (LTC4) in cancer cells: implications in drug resistance.
    Sharma R; Singhal SS; Wickramarachchi D; Awasthi YC; Awasthi S
    Int J Cancer; 2004 Dec; 112(6):934-42. PubMed ID: 15386349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determinants of differential doxorubicin sensitivity between SCLC and NSCLC.
    Singhal SS; Wickramarachchi D; Singhal J; Yadav S; Awasthi YC; Awasthi S
    FEBS Lett; 2006 Apr; 580(9):2258-64. PubMed ID: 16579994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glutathione-conjugate transport by RLIP76 is required for clathrin-dependent endocytosis and chemical carcinogenesis.
    Singhal SS; Wickramarachchi D; Yadav S; Singhal J; Leake K; Vatsyayan R; Chaudhary P; Lelsani P; Suzuki S; Yang S; Awasthi YC; Awasthi S
    Mol Cancer Ther; 2011 Jan; 10(1):16-28. PubMed ID: 21220488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RLIP76: a versatile transporter and an emerging target for cancer therapy.
    Vatsyayan R; Lelsani PC; Awasthi S; Singhal SS
    Biochem Pharmacol; 2010 Jun; 79(12):1699-705. PubMed ID: 20097178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of RLIP76 in lung cancer doxorubicin resistance: III. Anti-RLIP76 antibodies trigger apoptosis in lung cancer cells and synergistically increase doxorubicin cytotoxicity.
    Awasthi S; Singhal SS; Singhal J; Yang Y; Zimniak P; Awasthi YC
    Int J Oncol; 2003 Apr; 22(4):721-32. PubMed ID: 12632061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.